Biomarin Pharmaceutical Inc at Bank of America Merrill Lynch Health Care Conference Transcript
Welcome to the day 2 of the Bank of America Merrill Lynch Healthcare Conference in Vegas. My name Ying Huang, and I'm the large cap biotech analyst here in the U.S. covering U.S. biotech companies.
We're very pleased to have our next presenting company, which is BioMarin Pharmaceutical. We have the CEO and the Chairman, J.J. Bienaimé, on behalf of the company.
I believe J.J. has some prepared remarks to go over some of the very topical discussion about the 3-year update of valrox as a gene therapy for hemophilia A, and then after that we'll go into Q&A.
So with that, let me welcome J.J. to the podium. Thanks for coming.
©,-&
Thank you, Ying. Good morning, everybody. I might have to turn a little bit from time to time because the other screen is a little far away so -- to look at the screen.
I just want to, usual, let
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
